Skip to main content
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. — Investor Relations & Filings

Ticker · PTHS ISIN · US1711261057 US Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country US United States of America
Listing US PTHS

About Pelthos Therapeutics Inc.

https://ir.pelthos.com/

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for patients with unmet medical needs. Its lead product is ZELSUVMI™ (berdazimer topical gel, 10.3%), the first FDA-approved, at-home prescription treatment for molluscum contagiosum. ZELSUVMI is based on the company's proprietary nitric oxide-releasing technology platform, NITRICIL™, which is also being utilized for a pipeline of other product candidates. The company's portfolio also includes the acquired asset Xepi (ozenoxacin) Cream, 1%.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 90% confidence The document is a Current Report on Form 8-K filed with the SEC, disclosing a Regulation FD disclosure of a press release and investor presentation. It does not contain substantive financial statements, earnings data, or proxy materials, nor is it an annual or quarterly report. It is a regulatory filing under the Exchange Act. Therefore, it falls under the fallback category “Regulatory Filings” (RNS).
2026-05-28 English
8-K
Board/Management Information Classification · 90% confidence The document is a Current Report on Form 8-K filed by Pelthos Therapeutics Inc. reporting (1) a change in its independent registered public accounting firm and (2) the termination and separation agreement of its Chief Financial Officer. These disclosures constitute announcements of changes in the company’s certifying accountant and senior management. Under the classification definitions, this falls squarely under Board/Management Information (MANG).
2026-05-21 English
8-K
Regulatory Filings Classification · 85% confidence The document is a SEC Form 8-K “Current Report” disclosing an earnings press release (Item 2.02) and an investor presentation (Item 7.01). It does not contain the full financial statements itself (e.g., a standalone quarterly or annual report), nor is it a proxy or dividend notice. It is a regulatory filing under the Exchange Act and serves as a catch-all for various disclosures. Therefore, it falls under the general “Regulatory Filings” category (RNS).
2026-05-14 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 14, 2026. It announces that the CEO will participate in investor meetings and that a presentation has been made available on the company's website. The document includes a press release and a company presentation as exhibits. There are no financial statements or detailed financial data included in the text. The document primarily serves as a disclosure of an event and the availability of a presentation, rather than the presentation or report itself. The length is 6925 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes current reports like Form 8-K that announce events or disclosures without substantive financial data.
2026-04-14 English
8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC by Pelthos Therapeutics Inc. The key content is the announcement of the appointment of a new Chief Financial Officer and related management changes. It includes details about the new CFO's background, employment agreement, and termination of the previous CFO. The document also includes a press release as an exhibit. There are no financial statements or financial performance data presented. The primary focus is on management changes, specifically the appointment and departure of senior officers. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). Therefore, this document should be classified as MANG with high confidence.
2026-04-10 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.